Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - Micardis Plus(R) - Effekte bei Zielorganschädigung (16 Abbildungen)
Übersicht


Zum ersten Bild Abb. 8: Telmisartan - Renoprotektiver Effekt Abb. 9: Telmisartan - Renoprotektiver Effekt Abb. 10: Telmisartan - LVH Aktuelles Bild - Abb. 11: Telmisartan - LVH Abb. 12: Telmisartan - LVH Abb. 13: Telmisartan - LVH Abb. 14: Telmisartan - Arterienelastizität Zum letzten Bild
Abbildung 11: Telmisartan - LVH
This study used a freehand three-dimensional echocardiographic technique to evaluate the effect of telmisartan on left ventricular mass (LVM).1 The technique employs a magnetic sensor attached to an ultrasound probe to aid spatial location, which enables calculation of LVM without geometric assumptions. In this multicentre, randomized, double-blind study, 65 patients with hypertension received 12 months of treatment with either telmisartan 80 mg (n=40) or HCTZ 25 mg (n=25). Both drugs lowered blood pressure significantly: mean 24-h ambulatory SBP/DBP was reduced from baseline by 24/13 mmHg with telmisartan and by 10/8 mmHg with HCTZ. There was also a significant 16 g/m2 decrease in LVMI (from 141 ± 16 g/m2 to 125 ± 19 g/m2; p<0.02) in the telmisartan treatment group. However, the 4 g/m2 reduction in LVMI (from 139 ± 20 g/m2 to 135 ± 22 g/m2) observed in the HCTZ group was not statistically significant. Galzerano D, et al. Freehand three-dimensional echocardiographic assessment of efficacy of telmisartan on left ventricular mass in hypertensive patients: a multicentre study. J Hum Hypertens 2004; 18: 53–59.
 
Telmisartan - LVH
Vorheriges Bild Nächstes Bild   


Abbildung 11: Telmisartan - LVH
This study used a freehand three-dimensional echocardiographic technique to evaluate the effect of telmisartan on left ventricular mass (LVM).1 The technique employs a magnetic sensor attached to an ultrasound probe to aid spatial location, which enables calculation of LVM without geometric assumptions. In this multicentre, randomized, double-blind study, 65 patients with hypertension received 12 months of treatment with either telmisartan 80 mg (n=40) or HCTZ 25 mg (n=25). Both drugs lowered blood pressure significantly: mean 24-h ambulatory SBP/DBP was reduced from baseline by 24/13 mmHg with telmisartan and by 10/8 mmHg with HCTZ. There was also a significant 16 g/m2 decrease in LVMI (from 141 ± 16 g/m2 to 125 ± 19 g/m2; p<0.02) in the telmisartan treatment group. However, the 4 g/m2 reduction in LVMI (from 139 ± 20 g/m2 to 135 ± 22 g/m2) observed in the HCTZ group was not statistically significant. Galzerano D, et al. Freehand three-dimensional echocardiographic assessment of efficacy of telmisartan on left ventricular mass in hypertensive patients: a multicentre study. J Hum Hypertens 2004; 18: 53–59.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung